Meiogenix
Meiogenix is a biotech company developing breeding technologies to unlock the unexplored genetic diversity of organisms. The company expands the natural biodiversity and helps developing new products to address global food and industrial challenges.
Year of creation: 2010
Line of business: Biotechnology
Institut Curie: Behind the technology, institutional co-founder and R&D partner
TECHNOLOGY
Meiogenix's technologies improve the efficiency of molecular mechanisms of meiosis and accelerate the identification of novel variants of a given organisms.
SpiX technology modulates the process of homologous recombination in the genome by increasing its frequency in cold regions. By stimulating the process in regions of rare exchange, SpiX can unlock unexplored genetic diversity.
PhoeniX is a non-GM method that efficiently induces meiotic recombination in hybrid diploid (or polyploid) yeast cells without the need to go through the entire process of meiosis. PhoeniX relies on the capacity of a yeast cell to switch from meiosis to mitosis upon certain triggers (return-to-grow or RTG) and leads to highly diverse recombination profiles.
APPLICATIONS
Meiogenix's technologies adress global food and industrial challenges.
AMBITION
Meiogenix is currently applying its technologies through different R&D programs in plants and industrial yeast, and is developing complementary breakthrough technologies to control meiosis and recombination.
More about Meiogenix:
Co-founder of Meiogenix, Member of Institut Curie's Next Generation Sequencing and Telomeres and Cancer Teams
CEO of Meiogenix
Investor
Strategic Partner
Strategic Partner